Gkaliagkousi Eugenia, Gavriilaki Eleni, Douma Stella
2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Curr Hypertens Rep. 2015 Apr;17(4):536. doi: 10.1007/s11906-015-0536-2.
Antiplatelet agents represent a cornerstone in the management of patients at increased cardiovascular risk. Essential hypertension is considered a major public health problem leading to increased cardiovascular morbidity and mortality. The majority of patients with essential hypertension exhibit also additional cardiovascular risk factors and present with increased platelet activation. Despite recent innovations in the field of antiplatelet treatment and the introduction of novel agents, the role of antiplatelet treatment in patients with essential hypertension remains understudied. This review aims to shed light on novel experimental and clinical data in the evolving field of antiplatelet treatment in essential hypertension. In particular, recent data regarding aspirin, clopidogrel, novel P2Y12 inhibitors, and other agents with potential antiplatelet effects are critically reviewed.
抗血小板药物是管理心血管风险增加患者的基石。原发性高血压被认为是一个主要的公共卫生问题，会导致心血管发病率和死亡率增加。大多数原发性高血压患者还存在其他心血管危险因素，且血小板活化增加。尽管抗血小板治疗领域最近有创新并引入了新型药物，但抗血小板治疗在原发性高血压患者中的作用仍未得到充分研究。本综述旨在阐明原发性高血压抗血小板治疗这一不断发展领域中的新实验和临床数据。特别是，对近期有关阿司匹林、氯吡格雷、新型P2Y12抑制剂以及其他具有潜在抗血小板作用药物的数据进行了批判性综述。
